ATE469985T1 - Verfahren zur untersuchung der empfindlichkeit einer krebszelle gegenüber einem antikrebsmittel - Google Patents

Verfahren zur untersuchung der empfindlichkeit einer krebszelle gegenüber einem antikrebsmittel

Info

Publication number
ATE469985T1
ATE469985T1 AT05710143T AT05710143T ATE469985T1 AT E469985 T1 ATE469985 T1 AT E469985T1 AT 05710143 T AT05710143 T AT 05710143T AT 05710143 T AT05710143 T AT 05710143T AT E469985 T1 ATE469985 T1 AT E469985T1
Authority
AT
Austria
Prior art keywords
cancer cell
sensitivity
present compound
cancer
studying
Prior art date
Application number
AT05710143T
Other languages
English (en)
Inventor
Toshimitsu Uenaka
Masao Iwata
Original Assignee
Eisai R&D Man Co Ltd
Mercian Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd, Mercian Corp filed Critical Eisai R&D Man Co Ltd
Application granted granted Critical
Publication of ATE469985T1 publication Critical patent/ATE469985T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
AT05710143T 2004-02-06 2005-02-04 Verfahren zur untersuchung der empfindlichkeit einer krebszelle gegenüber einem antikrebsmittel ATE469985T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004030106 2004-02-06
JP2004069384 2004-03-11
PCT/JP2005/002091 WO2005075681A1 (ja) 2004-02-06 2005-02-04 抗癌剤に対する癌細胞の感受性を検定する方法

Publications (1)

Publication Number Publication Date
ATE469985T1 true ATE469985T1 (de) 2010-06-15

Family

ID=34840150

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05710143T ATE469985T1 (de) 2004-02-06 2005-02-04 Verfahren zur untersuchung der empfindlichkeit einer krebszelle gegenüber einem antikrebsmittel

Country Status (6)

Country Link
US (1) US20080280288A1 (de)
EP (1) EP1712642B1 (de)
AT (1) ATE469985T1 (de)
DE (1) DE602005021617D1 (de)
ES (1) ES2343843T3 (de)
WO (1) WO2005075681A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008016187A1 (en) * 2006-08-02 2008-02-07 Eisai R & D Management Co., Ltd. Pladienolide target molecule, compound capable of binding to the target molecule, and screening method for the compound
US7790887B2 (en) * 2007-01-29 2010-09-07 Eisai R&D Management Co., Ltd. Macrolide compound in solid form, process for preparation thereof, and pharmaceutical composition containing the same
WO2008111464A1 (ja) * 2007-03-05 2008-09-18 Eisai R & D Management Co., Ltd. スプライシング異常を指標とする抗ガン剤の作用検定方法
JPWO2008111466A1 (ja) * 2007-03-05 2010-06-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 遺伝子の発現量減少を指標とする抗ガン剤の作用検定方法
JP2009092508A (ja) * 2007-10-09 2009-04-30 Norihiro Nishimoto リウマチ治療剤の効果の予測方法
CN103076453B (zh) * 2012-12-24 2015-04-15 何以丰 P16免疫细胞化学试剂盒及其制备用多肽序列
CA3096400A1 (en) 2018-04-09 2019-10-17 Eisai R&D Management Co., Ltd. Certain pladienolide compounds and methods of use
CA3096424A1 (en) 2018-04-12 2019-10-17 Eisai R&D Management Co., Ltd. Pladienolide derivatives as spliceosome targeting agents for treating cancer
CN119405833A (zh) 2018-06-01 2025-02-11 卫材R&D管理有限公司 剪接调节抗体-药物缀合物及其使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5897999A (en) * 1996-03-22 1999-04-27 The Johns Hopkins University Cancer drug screen based on cell cycle uncoupling
AU2409602A (en) * 2000-11-24 2002-06-03 Eisai C0 Ltd Method of testing anticancer agent-sensitivity of tumor cells
TWI312681B (en) * 2001-02-01 2009-08-01 Novel physiologically active substance
TWI334866B (en) * 2002-05-29 2010-12-21 Mercian Corp Novel physiologically active substances
RU2338741C2 (ru) * 2002-07-31 2008-11-20 Мершан Корпорейшн Новые физиологически активные вещества

Also Published As

Publication number Publication date
EP1712642A4 (de) 2008-05-14
ES2343843T3 (es) 2010-08-11
DE602005021617D1 (de) 2010-07-15
EP1712642B1 (de) 2010-06-02
US20080280288A1 (en) 2008-11-13
EP1712642A1 (de) 2006-10-18
WO2005075681A1 (ja) 2005-08-18

Similar Documents

Publication Publication Date Title
EP1819227A4 (de) Pharmazeutische formulierungen von decitabin
Chesnokov et al. Anti-cancer activity of glucosamine through inhibition of N-linked glycosylation
CY1116610T1 (el) Ετεροδιμερη γλουτamiνiκου οξεος
TR200002796T2 (tr) Aminosikloheksil eter bileşikleri ve bunların kullanımları.
UA110347C2 (uk) ПОХІДНІ 6-ЦИКЛОАЛКІЛ-1,5-ДИГІДРОПІРАЗОЛО[3,4-d]ПІРИМІДИН-4-ОНУ І ЇХ ЗАСТОСУВАННЯ ЯК ІНГІБІТОРІВ PDE9A
EA201070929A1 (ru) ФУРО- И ТИЕНО[3,2-c]ПИРИДИНЫ
Bao et al. Targeting CSCs within the tumor microenvironment for cancer therapy: a potential role of mesenchymal stem cells
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
DE602005021617D1 (de) Verfahren zur untersuchung der empfindlichkeit einer krebszelle gegenüber einem antikrebsmittel
CY1109366T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης
BR112022020500A2 (pt) Corantes de cianina de infravermelho próximo e conjugados dos mesmos
PE20110001A1 (es) Derivados de taxanos como agentes citotoxicos
MA29653B1 (fr) Nouveaux composes analogues de la camptothecine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
Sandra et al. Conditioned media of human umbilical cord blood mesenchymal stem cell-derived secretome induced apoptosis and inhibited growth of HeLa cells
Narayanan et al. Effects of bioactive compounds from marine algae on cancer-related inflammation: a review
RU2013118021A (ru) Способы и композиции для лечения сахарного диабета и дислипидемии
EA200601846A1 (ru) Содержащие бензоксазины лекарственные комбинации для лечения заболеваний дыхательных путей
FR2903107B1 (fr) Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique
DE602007006419D1 (de) Verfahren zur verwendung von guava-extrakt und zusammensetzung mit guava-extrakt
Rashan et al. Molecular modes of action of an aqueous nerium oleander extract in cancer cells in vitro and in vivo
CA2458318A1 (en) Wortmannin analogs and methods of using same
Ahn et al. Amelioration of Particulate Matter-Induced Oxidative Stress by a Bioactive Hizikia fusiformis Extract: A Functional Biomaterial for Cosmeceutical Applications
Samant et al. The Ocean's Treasure Trove: Bioactive Compounds from Sea Sponges
CN1871227A (zh) 抗肿瘤剂
Akinlabi et al. Contractile effect of Aqueous Pleurotus Tuberregium Extract on the isolated bovine iris

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties